Investment Analysts’ Updated EPS Estimates for April 3rd (AAPL, ACI, ACIU, ADAG, ALT, ARQT, AXSM, BBY, CME, CTSO)

Investment Analysts’ updated eps estimates for Thursday, April 3rd:

Apple (NASDAQ:AAPL) had its buy rating reaffirmed by analysts at Rosenblatt Securities. They currently have a $263.00 price target on the stock.

Albertsons Companies (NYSE:ACI) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $23.00 price target on the stock.

AC Immune (NASDAQ:ACIU) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $16.00 target price on the stock.

Adagene (NASDAQ:ADAG) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $8.00 target price on the stock.

Altimmune (NASDAQ:ALT) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $12.00 target price on the stock.

Arcutis Biotherapeutics (NASDAQ:ARQT) had its buy rating reaffirmed by analysts at Guggenheim.

Arcutis Biotherapeutics (NASDAQ:ARQT) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $19.00 target price on the stock.

Arcutis Biotherapeutics (NASDAQ:ARQT) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $20.00 target price on the stock.

Axsome Therapeutics (NASDAQ:AXSM) had its buy rating reissued by analysts at HC Wainwright. They currently have a $200.00 price target on the stock.

Best Buy (NYSE:BBY) had its neutral rating reissued by analysts at Citigroup Inc.. Citigroup Inc. currently has a $70.00 price target on the stock, down from their previous price target of $93.00.

CME Group (NASDAQ:CME) had its sector perform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $269.00 target price on the stock.

Cytosorbents (NASDAQ:CTSO) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $1.00 price target on the stock.

CuriosityStream (NASDAQ:CURI) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $3.00 price target on the stock.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $36.00 price target on the stock.

Draganfly (NASDAQ:DPRO) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $7.00 target price on the stock.

Enlivex Therapeutics (NASDAQ:ENLV) had its buy rating reiterated by analysts at D. Boral Capital. They currently have a $13.00 target price on the stock.

Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $101.00 target price on the stock.

Ionis Pharmaceuticals (NASDAQ:IONS) had its buy rating reaffirmed by analysts at Guggenheim.

Lucid Group (NASDAQ:LCID) had its neutral rating reissued by analysts at Cantor Fitzgerald. They currently have a $3.00 target price on the stock.

Landstar System (NASDAQ:LSTR) had its hold rating reaffirmed by analysts at Benchmark Co..

Lululemon Athletica (NASDAQ:LULU) had its outperform rating reiterated by analysts at William Blair.

Netflix (NASDAQ:NFLX) had its buy rating reaffirmed by analysts at Guggenheim. Guggenheim currently has a $1,100.00 target price on the stock.

Oracle (NYSE:ORCL) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $220.00 target price on the stock.

Penguin Solutions (NASDAQ:PENG) had its buy rating reiterated by analysts at Rosenblatt Securities. They currently have a $27.00 target price on the stock.

Penguin Solutions (NASDAQ:PENG) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $27.00 target price on the stock.

Rani Therapeutics (NASDAQ:RANI) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $9.00 target price on the stock.

RH (NYSE:RH) had its neutral rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $200.00 target price on the stock, down from their previous target price of $437.00.

Ryvyl (NASDAQ:RVYL) had its neutral rating reaffirmed by analysts at HC Wainwright.

RxSight (NASDAQ:RXST) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $43.00 price target on the stock.

RxSight (NASDAQ:RXST) had its underperform rating reissued by analysts at Bank of America Co.. They currently have a $22.00 price target on the stock, down from their previous price target of $36.00.

Sachem Capital (NYSEAMERICAN:SACH) had its neutral rating reissued by analysts at LADENBURG THALM/SH SH.

Sportradar Group (NASDAQ:SRAD) had its buy rating reiterated by analysts at Guggenheim. They currently have a $27.00 target price on the stock.

Stagwell (NASDAQ:STGW) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $10.00 price target on the stock.

Stagwell (NASDAQ:STGW) had its buy rating reaffirmed by analysts at Rosenblatt Securities. The firm currently has a $10.00 target price on the stock.

Stagwell (NASDAQ:STGW) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $9.00 target price on the stock.

Tesla (NASDAQ:TSLA) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $425.00 target price on the stock.

Travere Therapeutics (NASDAQ:TVTX) had its overweight rating reissued by analysts at Cantor Fitzgerald.

U.S. Bancorp (NYSE:USB) had its underweight rating reissued by analysts at JPMorgan Chase & Co.. The firm currently has a $43.50 price target on the stock, down from their previous price target of $51.00.

Western Union (NYSE:WU) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $14.00 target price on the stock.

Yext (NYSE:YEXT) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $10.00 price target on the stock.